Regulatory Insights
Expert analysis on global health authority trends, competitive intelligence strategies, and the future of regulatory technology.
How Hospital Systems Track FDA Drug Approvals for Formulary Decisions
How hospital systems and health systems use FDA drug approval monitoring to support formulary decisions, drug procurement, and clinical pharmacy intelligence in 2026.
Top Regulatory Risks for Medtech Companies Entering the US Market
The top regulatory risks for medtech companies entering the US market in 2026 — covering 510(k) strategy, predicate selection, software, cybersecurity, EU MDR comparison, and post-market obligations.
EMA vs FDA — Key Differences for Medtech Market Access
EMA vs FDA for medtech market access in 2026 — a practical comparison covering pathways, approval timelines, clinical evidence requirements, EU MDR, and what competitive intelligence teams need to monitor.
How Medtech Companies Monitor FDA Device Approvals
How leading medtech companies monitor FDA device approvals in 2026 — covering 510(k), PMA, De Novo databases, monitoring workflows, and competitive intelligence tools for device teams.
510(k) Clearance Timeline — What to Expect in 2026
What to expect for 510(k) clearance timelines in 2026 — MDUFA V goals, average real-world timelines by device type, common causes of delay, and how medtech teams can benchmark against competitors.
How to Build a Regulatory Intelligence Workflow for Your Team
A step-by-step guide to building a regulatory intelligence workflow for pharma and medtech teams in 2026 — covering scope definition, source selection, monitoring cadences, and team structure.
Translate